verified SJR 1,612 · Q1 • database Scopus / SJR & Web of Science & DOAJ indexed

New Zealand · Dove Medical Press Ltd.

workspace_premium Q1 — Immunology and Allergy visibility_off Single blind Peer Review lock_open Open Access · DOAJ

Biologics: Targets and Therapy

Biologics: Targets and Therapy is a journal indexed in SJR in Immunology and Allergy and Oncology with an H index of 50. It is an CC BY-NC Journal with a Single blind Peer Review review system, and It has a price of 1762,2 €. The scope of the journal is focused on autoimmune diseases, cancer, biological agents. It has an SJR impact factor of 1,612 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,612.

ISSN: 1177-5475

Publisher: Dove Medical Press Ltd.

Category: Immunology and Allergy

Indexation: verifiedScopus / SJR verifiedWeb of Science verifiedDOAJ

open_in_new Portal NPD menu_book Author guidelines

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

1,612 Q1

H-index 50

Acceptance rate pie_chart

32%

Source Acceptance_Rate

Time to publication hourglass_top

16 weeks

Field Average_time_publication_weeks

Publication cost (APC) payments

1.762 € Open Access

Non-OA path NPD

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science DOAJ

SJR Impact

1,612

H-index

Docs (year)

Docs 3y

Total refs

2143

Cites 3y

491

Citable 3y

Cites/Doc 2y

3.23

Ref/Doc

61.23

Immediate OA

1762,2 €

Embargoed OA

NPD

Non OA / Submission

- €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Basiliximab induction therapy in kidney transplantation: Benefits for long term allograft function after 10 years?

Vitamins D, C, and E in the prevention of type 2 diabetes mellitus: modulation of inflammation and oxidative stress

Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS)

Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma

Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?

Clinical use of crizotinib for the treatment of non-small cell lung cancer

Clinical use of biologics in vasculitis syndromes

Clinical and comparative utility of afatinib in non-small cell lung cancer

Challenges in the management of juvenile idiopathic arthritis with etanercept

Botulinum toxin type A in the treatment of patients with cervical dystonia

Biological targets in the treatment of rheumatoid arthritis: a comprehensive review of current and in-development biological disease modifying anti-rheumatic drugs

Biologic targeting in the treatment of inflammatory bowel diseases

SHOW MORE ARTICLES

Bevacizumab in the treatment of ovarian cancer

A combined phase I and II open label study on the effects of a seaweed extract nutrient complex on osteoarthritis

B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab

B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis

Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia A

Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis

Anti-TNF therapy in Jordan: a focus on severe infections and tuberculosis

Anti-RhD immunoglobulin in the treatment of immune thrombocytopenia

Anti-interleukin-2 receptor antibodies-basiliximab and daclizumab-for the prevention of acute rejection in renal transplantation

An update on belimumab for the treatment of lupus

Advancing personalized care in hemophilia A: ten years" experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method

Adjuvant treatment with thyrotropin alpha for remnant ablation in thyroid cancer

FAQs

Biologics: Targets and Therapy has an SJR of 1,612 (best quartile Q1) in the CountryOfPapers database.

Immediate OA APC is 1762,2 EUR.

The acceptance rate recorded for Biologics: Targets and Therapy is 32%.

Biologics: Targets and Therapy

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Biologics: Targets and Therapy?

What is the APC / publication cost?

What is the acceptance rate?